Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
暂无分享，去创建一个
R. Huddart | B. Mellado | S. Park | A. Necchi | J. García-Donas | A. Siefker-Radtke | Y. Loriot | I. Durán | M. Fleming | E. Burgess | B. Zhong | A. Dosne | K. Stuyckens | M. Joshi | A. Rezazadeh | S. Varlamov | A. Avadhani | Anne OHagan